Camrelizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Camrelizumab
Accession Number
DB14776
Type
Biotech
Groups
Investigational
Description

Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

Synonyms
Not Available
External IDs
SHR-1210
Categories
UNII
73096E137E
CAS number
1798286-48-2

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Camrelizumab.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Camrelizumab.
AbrilumabThe risk or severity of adverse effects can be increased when Camrelizumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Camrelizumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Camrelizumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Camrelizumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Camrelizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Camrelizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Camrelizumab.
AmatuximabThe risk or severity of adverse effects can be increased when Amatuximab is combined with Camrelizumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Camrelizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingOtherLung Cancers1
1Active Not RecruitingTreatmentCancer, Breast / Gastrointestinal Cancers1
1Active Not RecruitingTreatmentNasopharyngeal Carcinoma1
1Active Not RecruitingTreatmentNeoplasms / Solid Tumors and Hematologic Malignancy1
1Enrolling by InvitationTreatmentNeoplasms1
1Not Yet RecruitingTreatmentAdvanced Gastric Cancer1
1Not Yet RecruitingTreatmentAdvanced Solid Tumors1
1Not Yet RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1Not Yet RecruitingTreatmentMetastatic Cancers / Neoplasms Malignant / Tumors, Solid1
1RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
1RecruitingTreatmentTumors, Solid1
1, 2Not Yet RecruitingTreatmentAdvanced Malignant Solid Tumor1
1, 2Not Yet RecruitingTreatmentCRC / HCC / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1, 2Not Yet RecruitingTreatmentEffect of Drugs / Pediatric Cancer / Progression1
1, 2RecruitingTreatmentHepatocellular,Carcinoma / Malignant Neoplasm of Stomach1
1, 2RecruitingTreatmentPrimary mediastinal large B-cell lymphomas1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentClinical Benefit Rate / Overall Survival / Progression-free Survival / Therapeutic Agent Toxicity1
2Active Not RecruitingTreatmentHepatocellular Carcinoma Non-resectable1
2Active Not RecruitingTreatmentHepatocellular,Carcinoma1
2Not Yet RecruitingTreatmentAFP / Malignant Neoplasm of Stomach1
2Not Yet RecruitingTreatmentChemotherapy Effect / KRAS Gene Mutation / NSCLC Stage IV / PD-1 Antibody1
2Not Yet RecruitingTreatmentEsophageal Cancers1
2Not Yet RecruitingTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
2Not Yet RecruitingTreatmentGastric Adenocarcinoma1
2Not Yet RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Not Yet RecruitingTreatmentNeoplasms, Lung1
2Not Yet RecruitingTreatmentSquamous Cell Carcinoma of Esophagus2
2RecruitingTreatmentAdvanced Biliary Tract Carcinoma / Advanced Primary Liver Cancer1
2RecruitingTreatmentBiliary Tract Cancer / Cholangiocarcinomas1
2RecruitingTreatmentCarcinoma, Bronchogenic / Chronic Lung Diseases / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasm, Bronchial / Neoplasms, Lung / Respiratory Tract Diseases / Respiratory tract neoplasms NEC1
2RecruitingTreatmentCervical Cancers / Endometrial Cancers / Recurrent Ovarian Cancer / Renal Cell Adenocarcinoma / Transitional Cell Carcinoma1
2RecruitingTreatmentClear Cell Renal Cell Carcinoma / Metastic Renal Cell Carcinoma / Second-line Treatment1
2RecruitingTreatmentEsophageal Diseases / Gastrointestinal Diseases / Neoplasms, Esophageal / Neoplasms, Gastrointestinal1
2RecruitingTreatmentGastrooesophageal Cancer / Malignant Neoplasm of Stomach1
2RecruitingTreatmentHepatocellular,Carcinoma1
2RecruitingTreatmentHodgkin Lymphoma, Adult1
2RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
2RecruitingTreatmentLymphoma, Hodgkins1
2RecruitingTreatmentMetastatic Colorectal Cancers1
2RecruitingTreatmentNasopharyngeal Carcinoma1
2RecruitingTreatmentRecurrent Cervical Carcinoma / Recurrent, IV-B Cervical cancer1
2RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2TerminatedTreatmentMetastatic Colorectal Cancers1
3Active Not RecruitingTreatmentOesophageal Carcinoma1
3Not Yet RecruitingTreatmentChemotherapy Effect / Lung Cancer Squamous Cell / Lung carcinoma cell type unspecified stage IV / PD-1 Antibody1
3Not Yet RecruitingTreatmentGastrooesophageal Cancer / Malignant Neoplasm of Stomach1
3Not Yet RecruitingTreatmentLocally Advanced or Metastatic and Unresectable HCC1
3RecruitingTreatmentAdvanced Esophageal Cancers1
3RecruitingTreatmentAdvanced Hepatocellular Carcinoma1
3RecruitingTreatmentCarcinoma, Bronchogenic / Chronic Lung Diseases / Lung Cancer Non-Small Cell Cancer (NSCLC) / Neoplasm, Bronchial / Neoplasms by Site / Neoplasms, Lung / Respiratory Tract Diseases / Respiratory Tract Neoplasms / Thoracic Neoplasms1
3RecruitingTreatmentNasopharyngeal Carcinoma1
3RecruitingTreatmentNasopharyngeal Neoplasms1
Not AvailableRecruitingPreventionHepatocellular,Carcinoma1
Not AvailableRecruitingTreatmentEsophageal Cancers2
Not AvailableRecruitingTreatmentHepatocellular,Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:26 / Updated on May 21, 2019 12:29